Protara Therapeutics

Historical price data

Protara Therapeutics is a clinical-stage biotech company with a mission to develop transformative therapies for cancer and rare diseases. Its strategy centers on advancing two distinct, late-stage clinical programs: TARA-002, an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a phospholipid substrate replacement for intestinal failure-associated liver disease. The company has achieved key milestones by initiating and enrolling multiple Phase 2 trials, positioning both assets for potential near-term data readouts. Protara's focused approach aims to address high-need, niche markets with limited treatment options.

Protara employs two distinct platforms: an intravesical live biotherapeutic product (LBP) platform for localized immune stimulation in cancer and lymphatic malformations, and an intravenous phospholipid substrate replacement platform for addressing metabolic deficiencies in rare liver disease.

In bladder cancer, TARA-002 competes with newer intravesical gene therapy and systemic immunotherapy, differentiating via its localized mechanism. In lymphatic malformations, it competes with invasive procedures. For IFALD, it faces no direct pharmacological competition, but must shift entrenched clinical practice paradigms.